Brisbane, California Saturday, April 5, 2025, 15:00 Hrs [IST] ...

The US FDA has granted accelerated approval to atrasentan (Vanrafia) for reducing proteinuria in adults with primary ...

Novartis’ Vanrafia (atrasentan) has been granted accelerated approval by the US Food and Drug Administration (FDA) to treat ...

Approval was based on results from the Phase III ALIGN study, which demonstrated a significant reduction in proteinuria at 36 ...

Today, a brief rundown of news involving Sarepta Therapeutics, Novartis and Allakos, as well as updates from CSL Behring and Roche that you may have missed.

Novartis stock popped Thursday — prompting Travere Therapeutics to slide — after winning FDA approval for a kidney disease treatment.

The FDA has granted accelerated approval to Vanrafia to reduce proteinuria in adults with primary IgAN at risk of rapid disease progression.

Astrasentan becomes the first and only endothelin A receptor antagonist to focus on proteinuria reduction in primary ...

FDA grants accelerated approval to Novartis' Vanrafia for IgA nephropathy, with Phase 3 data in 2026 expected to support ...

Edgar Lerma, MD, provides insights into the pathophysiology of IgA nephropathy (IgAN) and the therapeutic promise of ...

FDA grants accelerated approval for Novartis's Vanrafia (atrasentan) for IgA nephropathy. The drug joins Tarpeyo and Filspari as well as Novartis' own Fabhalta in treating this rare kidney disease.

Novartis ( NYSE: NVS) said on Thursday that it received US FDA's accelerated approval for Vanrafia as a treatment for adults ...